Sort
15,842 grants matching “pancreatic cancer”
NOVEL STRATEGIES TO IMPROVE LIVER CANCER SURVEILLANCE UPTAKE AND EARLY DETECTION
$658,591Anna Sf Lok · University Of Michigan At Ann Arbor · U01 · FY2019 · CA
Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.
$658,475Hak Soo Choi · Massachusetts General Hospital · R01 · FY2020 · EB
Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.
$658,475Hak Soo Choi · Massachusetts General Hospital · R01 · FY2019 · EB
Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor.
$658,473Hak Soo Choi · Massachusetts General Hospital · R01 · FY2018 · EB
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity
$658,369David G Denardo · Washington University · U01 · FY2023 · CA
Biological functions of chromosomal proteins
$657,985Michael Bustin · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
Targeting novel therapeutic vulnerabilities in LKB1 mutant tumors.
$657,955Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2019 · CA
DCE-MRI guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
$657,895Harrison Kim · Ohio State University · R01 · FY2025 · CA
Image guided intervention system for pancreatic cystic lesions
$657,842Nicusor Iftimia · Physical Sciences, Inc · R44 · FY2011 · CA
Study Of Factors That Induce Differentiation Of Pancreatic Precursor Cells
$657,837Marvin Gershengorn · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2009 · DK
Phenotypic marker-guided development of selective antimetastasis therapeutic leads
$657,810Sui Huang · Northwestern University At Chicago · R01 · FY2022 · CA
MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases
$657,713Wade M Junker · Sanguine Diagnostics And Therapeutics · R44 · FY2018 · DK
MUC4/16 assay for the early diagnosis and management of benign and malignant pancreatic diseases
$657,713Joshua James Souchek · Sanguine Diagnostics And Therapeutics · R44 · FY2019 · DK
A novel diagnostic biomarker for Hepatocellular Carcinoma(HCC)
$657,468Xuanyong Lu · Imcare Biotech, Inc. · R44 · FY2016 · CA
Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer
$657,258Robert H Vonderheide · University Of Pennsylvania · R01 · FY2021 · CA
Mechanisms of JAG1-mediated immune suppression in the pancreatic cancer microenvironment
$657,074Lan Zhou · Methodist Hospital Research Institute · R01 · FY2025 · CA
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$657,066James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Integrating Epigenetic Modulation into DNA Damage Repair
$656,890Pamela N Munster · University Of California, San Francisco · R01 · FY2022 · CA
Intervention of Pancreatic Oncogenic Pathways with Dietary Tocotrienol
$656,718Mokenge P. Malafa · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2010 · CA
CCR FACS Core Laboratory
$656,486Barbara Taylor · Division Of Basic Sciences - Nci · ZIC · FY2009 · CA
Role of FH loss in development of HLRCC heriditary kidney cancer
$656,408Leonard Neckers · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Utilizing nucleic acid scavengers to elucidate how DNA/RNA-containing DAMPs promote pancreatic cancer metastasis and to mitigate such processes
$656,237Bruce Alan Sullenger · Duke University · R01 · FY2024 · CA
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$656,180Diane M Simeone · New York University School Of Medicine · R01 · FY2023 · CA
Centralization of Cancer Care: Implications for Access, Outcomes, and Disparities
$656,146Bruce L. Jacobs · University Of Pittsburgh At Pittsburgh · R37 · FY2022 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$656,048Dung T Le · Johns Hopkins University · P01 · FY2023 · CA